MAGOH: A Protein Targeted for Cancer and Other Diseases (G4116)

Target Name: MAGOH

NCBI ID: G4116

MAGOH

MAGOH: A Protein Targeted for Cancer and Other Diseases

MAGOH (MAGOHA) is a protein that is expressed in various tissues of the body, including the brain, heart, and liver. It is a key regulator of the cell cycle, and is involved in the development and progression of many diseases, including cancer.

One of the most exciting aspects of MAGOH is its potential as a drug target. MAGOH has been shown to play a role in a wide range of cellular processes, including cell division, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels). It is also involved in the regulation of inflammation and immune responses.

MAGOH has been shown to be highly expressed in many types of cancer, including breast, ovarian, and colorectal cancers. It is often overexpressed (above its normal level) in these cancers, which can lead to the development of a more aggressive and deadly form of the disease.

In addition to its potential as a drug target, MAGOH has also been shown to be a potential biomarker for cancer. Its expression has been shown to be associated with the development of many types of cancer, including breast, ovarian, and colorectal cancers. It may also be a useful biomarker for tracking the effectiveness of certain treatments.

One of the challenges in studying MAGOH is its complex structure and function. MAGOH is a transmembrane protein that is involved in a wide range of cellular processes. It consists of multiple domains, including an extracellular domain that is involved in cell adhesion and signaling, a transmembrane domain that is involved in the regulation of the cell cycle, and an intracellular domain that is involved in the regulation of DNA replication and gene expression.

MAGOH has been shown to play a key role in the regulation of the cell cycle. It is involved in the metaphase (the stage of cell division where the chromosomes are replicated), and in the anaphase (the stage of cell division where the chromosomes are separated and divided between the daughter cells). MAGOH has been shown to play a key role in the regulation of the anaphase checkpoint, which is a critical step in the cell cycle that ensures that the correct number of chromosomes are passed on to the daughter cells.

MAGOH is also involved in the regulation of apoptosis, which is the process by which cells die and are removed from the body. It is shown to play a key role in the regulation of apoptosis, and is involved in the formation of apoptotic structures, such as the endoplasmic reticulum, which is the body's natural mechanism for removing damaged or dysfunctional cells.

MAGOH is also involved in the regulation of inflammation and immune responses. It has been shown to play a key role in the regulation of T cell development and function, and is involved in the regulation of the production of antibodies (immunoglobulins) by B cells.

In conclusion, MAGOH is a protein that is involved in a wide range of cellular processes, including cell division, apoptosis, and inflammation. Its potential as a drug target and biomarker for cancer makes it an attractive target for further research. Further studies are needed to fully understand its role in these processes and to develop effective treatments.

Protein Name: Mago Homolog, Exon Junction Complex Subunit

Functions: Required for pre-mRNA splicing as component of the spliceosome (PubMed:11991638). Plays a redundant role with MAGOHB as core component of the exon junction complex (EJC) and in the nonsense-mediated decay (NMD) pathway (PubMed:23917022). The EJC is a dynamic structure consisting of core proteins and several peripheral nuclear and cytoplasmic associated factors that join the complex only transiently either during EJC assembly or during subsequent mRNA metabolism. The EJC marks the position of the exon-exon junction in the mature mRNA for the gene expression machinery and the core components remain bound to spliced mRNAs throughout all stages of mRNA metabolism thereby influencing downstream processes including nuclear mRNA export, subcellular mRNA localization, translation efficiency and nonsense-mediated mRNA decay (NMD). The MAGOH-RBM8A heterodimer inhibits the ATPase activity of EIF4A3, thereby trapping the ATP-bound EJC core onto spliced mRNA in a stable conformation. The MAGOH-RBM8A heterodimer interacts with the EJC key regulator PYM1 leading to EJC disassembly in the cytoplasm and translation enhancement of EJC-bearing spliced mRNAs by recruiting them to the ribosomal 48S preinitiation complex. Involved in the splicing modulation of BCL2L1/Bcl-X (and probably other apoptotic genes); specifically inhibits formation of proapoptotic isoforms such as Bcl-X(S); the function is different from the established EJC assembly

The "MAGOH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAGOH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets